Kai Medical-B (02105.HK) has granted a total of 11.46 million restricted share units.

Zh tng cijng APP xn, li ki yyo -B (02105.HK) fb gnggo, y 2025 nin 5 yu 8 r, gnj 2024 nin gfn jingl jhu xing chngshu rn (boku 3 mng xngzh dngsh) gich h gng 1146 wn fn shuxin gfn dnwi (xingdng y h gng 1146 wn g gfn). Xing boku l xingyng, xi lng j g xingj zi ni de 3 mng xngzh dngsh gich shuxin gfn dnwi x di tbi gfn zi gfn zhunan dhu shng pzhn hu, fngk zu sh. Zhtng Finance APP News, Lai Kai Pharmaceutical -B (02105.HK) announced that on May 8, 2025, a total of 11.46 million restricted stock units (equivalent to a total of 11.46 million shares) were granted to grantees (including 3 executive directors) in accordance with the 2024 stock incentive plan. The grant of restricted stock units to the 3 executive directors including Lv Xiangyang, Xie Ling, and Gu Xiangju must be approved by independent shareholders at the annual general meeting before it can take effect.